Market Closed -
BME
12:35:12 2024-03-28 pm EDT
5-day change
1st Jan Change
28.74
EUR
+0.63%
0.00%
-30.04%
Sales 2024 *
171M
184M
Sales 2025 *
200M
215M
Capitalization
507M
547M
Net income 2024 *
5M
5.39M
Net income 2025 *
56M
60.42M
EV / Sales 2024 *
2.29
x
Net cash position
2024
*
116M
125M
Net cash position
2025
*
193M
208M
EV / Sales 2025 *
1.57
x P/E ratio 2024 *
84.5
x
P/E ratio 2025 *
11.2
x
Employees
509
Yield 2024 *
2.26%
Yield 2025 *
1.71%
Free-Float
76.54%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024
Feb. 29
Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 27
CI
Pharma Mar's Sylentis Meets Primary Endpoint for Dry Eye Disease Medication
Dec. 18
MT
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong
Dec. 12
MT
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao
Dec. 04
MT
Pharma Mar's Partner Wins Commercialization Approval for Zepzelca in Peru
Nov. 07
MT
PharmaMar Gets $10 Million Milestone Payment from Janssen Under Yondelis Licensing Deal
Nov. 06
MT
Transcript : Pharma Mar, S.A., Q3 2023 Earnings Call, Oct 27, 2023
23-10-27
Pharma Mar, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-25
CI
Pharma Mar, S.A. commences an Equity Buyback Plan, under the authorization approved on May 31, 2023.
23-09-05
CI
Transcript : Pharma Mar, S.A., H1 2023 Earnings Call, Jul 28, 2023
23-07-28
Pharma Mar, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023
23-07-27
CI
PharmaMar Secures Taiwan Regulatory Approval for Lung Cancer Treatment
23-07-11
MT
Pharma Mar Recruits First Patient for Solid Tumor Treatment Trial
23-05-04
MT
Transcript : Pharma Mar, S.A., Q1 2023 Earnings Call, Apr 27, 2023
23-04-27
More news
OPINIONES DE LOS ANALISTAS DEL DÍA : Adyen, Endesa, Viscofan, Iberdrola, Repsol, Pharma Mar, NH Hotel, Nemetschek, Société Générale...
Feb. 09
Bolsa de Madrid: Caramba, ¡falló otra vez!
Feb. 09
EN DIRECTO DESDE LOS MERCADOS: Pharma Mar, Repsol, Cie Automotive, Alphabet, UBS, Acciona, Richemont, Covestro, Apple...
Dec. 19
EN DIRECTO DESDE LOS MERCADOS: Pharma Mar, Sacyr, LVMH, Iberdrola, Dufry, Berkshire Hathaway, Ryanair, Telecom Italia
Nov. 06
OPINIONES DE LOS ANALISTAS DEL DÍA : Amadeus, Sacyr, Nokia, Telefónica, Pharma Mar, Novo Nordisk, Rheinmetall, Prosegur, Almirall, Vodafone...
23-10-11
More news 1 day +0.63%
Current month -5.46%
1 month -14.46%
3 months -32.44%
6 months -10.19%
Current year -30.04%
More quotes
Managers
Title Age Since
Chief Executive Officer
-
86-04-29
Director of Finance/CFO
-
87-12-31
Chief Tech/Sci/R&D Officer
-
-
Members of the board
Title Age Since
Chief Executive Officer
-
86-04-29
Director/Board Member
-
86-04-29
Director/Board Member
-
-
More insiders
Date
Price
Change
Volume
24-03-28
28.74
+0.63%
37,220
24-03-27
28.56
+1.49%
45,156
24-03-26
28.14
+0.36%
32,659
24-03-25
28.04
-1.54%
35,438
24-03-22
28.48
-1.18%
53,021
Delayed Quote
BME, March 28, 2024 at 12:35 pm EDT
More quotes
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company's product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
More about the company
Last Close Price
28.74
EUR
Average target price
49.4
EUR
Spread / Average Target
+71.89%
Consensus
1st Jan change
Capi.
-30.04% 545M +0.44% 90.27B +9.61% 44.05B -16.67% 31.45B +44.99% 23.35B -9.42% 16.72B -25.92% 15.09B -9.27% 12.82B -7.57% 11.95B +0.07% 8.71B
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1